fluticasone furoate/vilanterol vs Fluticasone propionate/salmeterol (Advair Diskus)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
fluticasone furoate/vilanterol · Breo Ellipta
Marketed by GlaxoSmithKline
NCT01313676 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 16,568 participants, with all-cause mortality as an objective clinical primary endpoint. However, the fluticasone furoate/vilanterol versus placebo comparison did not meet statistical significance (hazard ratio 0.878, p=0.137), and the record does not report a power calculation.
Reported efficacy
Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants (missed)
Result source: NCT01313676
Fluticasone propionate/salmeterol (Advair Diskus)
Marketed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/vilanterol | Fluticasone propionate/salmeterol (Advair Diskus) |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | —Not reported |
| Trough FEV1, change | —Not reported | —Not reported |
| SGRQ total, change | —Not reported | —Not reported |
| TDI focal score | —Not reported | —Not reported |
Moderate or severe exacerbations, annualised rate
- fluticasone furoate/vilanterol
- —Not reported
- Fluticasone propionate/salmeterol (Advair Diskus)
- —Not reported
Trough FEV1, change
- fluticasone furoate/vilanterol
- —Not reported
- Fluticasone propionate/salmeterol (Advair Diskus)
- —Not reported
SGRQ total, change
- fluticasone furoate/vilanterol
- —Not reported
- Fluticasone propionate/salmeterol (Advair Diskus)
- —Not reported
TDI focal score
- fluticasone furoate/vilanterol
- —Not reported
- Fluticasone propionate/salmeterol (Advair Diskus)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Fluticasone propionate/salmeterol (Advair Diskus): registry results are on file for Chronic Obstructive Pulmonary Disease, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Asthma
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline
fluticasone furoate/vilanterol · Breo Ellipta
Marketed by GlaxoSmithKline
NCT01086384 · Phase 3 · completed
This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.
Reported efficacy
Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 (met)
Result source: NCT01086384
Fluticasone propionate/salmeterol (Advair Diskus)
Marketed by GlaxoSmithKline
NCT00920959 · Phase 3 · completed
This was a well-designed, randomized, double-blind, placebo-controlled trial with a reasonably large sample (908 participants) and a lung-function primary endpoint, which is the kind of objective physiological measure regulators accept for asthma trials. However, the key comparison -- showing that the fluticasone/salmeterol combination improved peak flow more than fluticasone alone -- did not reach statistical significance, so despite the strong design the result itself was a null finding rather than a demonstrated benefit.
Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.
Reported efficacy
Change from baseline at endpoint in daily PM PEF (12 weeks): Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) (missed)
Result source: NCT00920959
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/vilanterol | Fluticasone propionate/salmeterol (Advair Diskus) |
|---|---|---|
| Severe exacerbations, annualised rate | —Trial running · NCT05757102 | 2.6 vs 2.7vs FP DISKUSNCT00452348 |
| Trough FEV1, change | 0.4 vs 0.2+0.2 vs placeboNCT011651388 other results
| 0.1 vs 0.1vs FF/VINCT029246885 other results
|
| ACQ-5, change | -1.2 vs -1.1vs FFNCT032481281 other result
| —Not posted · NCT00920959 |
| OCS dose reduction | —Trial running · NCT05757102 | —Not posted · NCT00920959 |
Severe exacerbations, annualised rate
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
- Fluticasone propionate/salmeterol (Advair Diskus)
- 2.6 vs 2.7vs FP DISKUSNCT00452348
Trough FEV1, change
- fluticasone furoate/vilanterol
- 0.4 vs 0.2+0.2 vs placeboNCT01165138
8 other results
- 0.4 vs 0.2 NCT01134042
- 0.5 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT01147848
- 0.3 vs 0.3 NCT01086384
- 0.4 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT03248128
- -0.1 vs -0.1 NCT02094937
- 0.3 vs 0.2 NCT03248128
- Fluticasone propionate/salmeterol (Advair Diskus)
- 0.1 vs 0.1vs FF/VINCT02924688
5 other results
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT02924688
- 0.2 vs 0.1 NCT02924688
- 0.1 vs -0.1 NCT00557440
- 0.2 vs 0.1 NCT00452348
ACQ-5, change
- fluticasone furoate/vilanterol
- -1.2 vs -1.1vs FFNCT03248128
1 other result
- -1.3 vs -1.1 NCT03248128
- Fluticasone propionate/salmeterol (Advair Diskus)
- —Not posted · NCT00920959
OCS dose reduction
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
- Fluticasone propionate/salmeterol (Advair Diskus)
- —Not posted · NCT00920959
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety
Coverage. fluticasone furoate/vilanterol: 12 of 12 rows · Fluticasone propionate/salmeterol (Advair Diskus): 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/vilanterol Rows use multiple source trials | Fluticasone propionate/salmeterol (Advair Diskus) Rows use multiple source trials |
|---|---|---|
| ACT Control responder rate · % of participants | 92% (n=471) vs 93% (n=467) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence | 92% (n=471) vs 93% (n=467) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence |
| ACT Total absolute change · score | 4.4 vs 2.5 placebo score @ 12wk100/25 µg ODa,b NCT01165138 · Phase 3 | 5.4 vs 4.5 placebo score @ 12wk50/12.5 mcg BIDa,b NCT02980133 · Phase 3 · registry result, not featured evidence |
| AM PEF Change L/Min absolute change · L/min | 8.9 vs 3.7 FP/S L/min @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence | 8.9 vs 3.7 FP/S L/min @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence |
| Evening PEF absolute change · L/min | 26.4 vs -1.8 placebo L/min @ 12wk100/25 µg ODc,a,b,d NCT01165138 · Phase 3 2 other source trials39.7 vs 15.5 FF L/min @ 12wk100/25 µg OD NCT01686633 · Phase 3 41.7 vs 15.5 FF L/min @ 12wk200/25 µg OD NCT01686633 · Phase 3 | 10.8 vs 7.6 FP L/min @ 4wk100/50mcg BIDc,a,b,d NCT00118716 · Phase 4 · registry result, not featured evidence |
| Evening PEF Change L/Min absolute change · L/min | 5.5 vs 0.5 FP/S L/min @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence | 5.5 vs 0.5 FP/S L/min @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence |
| FEV1 absolute change · L | 0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailye,a,b NCT02301975 · Phase 3 · registry result, not featured evidence show 1 more dose0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence | 0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailye,a,b NCT02301975 · Phase 3 · registry result, not featured evidence show 1 more dose0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence |
| Rescue-free 24-h Period percent change · % of baseline | -3% (n=500) vs -4.2% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence | -3% (n=500) vs -4.2% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence |
| Symptom-free 24 h Periods absolute change · percentage points | -3.5% (n=500) vs -4.7% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence | -3.5% (n=500) vs -4.7% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence |
| Dropout rate | —100/25 µgf NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 10.9%100/25 µg OD NCT01165138 · Phase 3 7.2%200/25 µg OD NCT01686633 · Phase 3 9.2%100/25 µg OD NCT01686633 · Phase 3 14.2%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 14.4%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 12.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | 0.2%g NCT01475721 · Phase 4 show 14 more results25.5%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 2.8%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 7.7%100/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.9%200/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence —100mcg/50mcg NCT00927758 · Phase 2 · registry result, not featured evidence — NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 |
| Discontinued due to AEs | —100/25 µgf NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 1%100/25 µg OD NCT01165138 · Phase 3 0.9%200/25 µg OD NCT01686633 · Phase 3 0.9%100/25 µg OD NCT01686633 · Phase 3 3.6%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 2.6%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 1.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | —g NCT01475721 · Phase 4 show 14 more results1.9%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence —50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 0.7%100/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0.7%200/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0.5%100/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0.5%200/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence —100mcg/50mcg NCT00927758 · Phase 2 · registry result, not featured evidence — NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 |
| Serious AEs | 4.1%100/25 µgf NCT01086384 · Phase 3 show 16 more results0.5%200/25 µg OD NCT01018186 · Phase 3 1.5%100/25 µg OD NCT01018186 · Phase 3 1.1% NCT03248128 · Phase 3 · Asthma · phase 3 0%100/25 µg OD NCT01165138 · Phase 3 0.3%200/25 µg OD NCT01686633 · Phase 3 1.2%100/25 µg OD NCT01686633 · Phase 3 3%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 1%100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 1.4%100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 1.3%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 0.6%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0%100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | 2.3%g NCT01475721 · Phase 4 show 14 more results2.3%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence 2%50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence 0%100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 1.9%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 4.4%100/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.1%200/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence 0%250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 0%250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 0.6%100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 0%100mcg/50mcg NCT00927758 · Phase 2 · registry result, not featured evidence 0% NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 |
| Most frequent reported AEs | 100/25 µgf headache 18.6% nasopharyngitis 15.4% upper respiratory tract infection 7.2% NCT01086384 · Phase 3 show 15 more results200/25 µg OD headache 17.3% upper respiratory tract infection 14.9% nasopharyngitis 9.4% NCT01018186 · Phase 3 100/25 µg OD headache 19.4% upper respiratory tract infection 16.9% nasopharyngitis 12.4% NCT01018186 · Phase 3 nasopharyngitis 10.4% upper respiratory tract infection 7% rhinitis allergic 4.2% NCT03248128 · Phase 3 · Asthma · phase 3 200/25 µg OD headache 8.4% nasopharyngitis 7.2% upper respiratory tract infection 2% NCT01686633 · Phase 3 100/25 µg OD headache 8.4% nasopharyngitis 6.4% upper respiratory tract infection 2.3% NCT01686633 · Phase 3 200/25 µg OD nasopharyngitis 12.7% headache 5.6% bronchitis 3.6% NCT01134042 · Phase 3 · combination · Asthma · phase 3 100/25 µg OD nasopharyngitis 11.4% headache 8.4% upper respiratory tract infection 6.2% NCT01147848 · Phase 3 · Asthma · phase 3 100/25 µg QD upper respiratory tract infection 6.8% NCT02730351 · Phase 4 · registry result, not featured evidence 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 100/25 µg Once Daily upper respiratory tract infection 7.2% (placebo 9.1%) headache 4.6% (placebo 1.9%) nasopharyngitis 4.6% (placebo 8.4%) NCT01498679 · Phase 3 · registry result, not featured evidence 200/25 µg Once Daily upper respiratory tract infection 8.4% nasopharyngitis 3.9% rhinitis allergic 3.2% NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100 µg/25 µg bronchitis 4% conjunctivitis 4% headache 4% NCT01453023 · Phase 2 · registry result, not featured evidence | show 14 more results250/50 mcg BID nasopharyngitis 17.4% headache 16.5% upper respiratory tract infection 14.5% NCT00452348 · Phase 4 · registry result, not featured evidence 50/100 mcg BD headache 18% nasopharyngitis 9.3% rhinitis 8% NCT00353873 · Phase 4 · registry result, not featured evidence 100/50mcg BID headache 3.2% upper respiratory tract infection 3.2% abdominal pain upper 2.4% NCT00118716 · Phase 4 · registry result, not featured evidence 50/12.5 mcg BID nasopharyngitis 4.3% (placebo 5.3%) NCT02980133 · Phase 3 · registry result, not featured evidence 100/31.25/25 mcg nasopharyngitis 13.8% headache 7.7% upper respiratory tract infection 5.9% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 200/31.25/25 mcg nasopharyngitis 12.6% headache 6.7% bronchitis 4% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 14.8% headache 8.9% bronchitis 3.7% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 200/62.5/25 mcg nasopharyngitis 12.5% bronchitis 5.4% headache 4.7% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 250/50 mcg BID headache 11% hypertension 6.1% blood pressure increased 0% NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 250/50 mcg BID headache 12.2% hypertension 4.9% blood pressure increased 3.7% NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 100/50 HFA headache 15% nasopharyngitis 9.2% upper respiratory tract infection 6.4% NCT00441441 · Phase 3 · registry result, not featured evidence 100mcg/50mcg cough 5% upper respiratory infection 5% viral upper respiratory infection 5% NCT00927758 · Phase 2 · registry result, not featured evidence headache 5.6% (placebo 5.4%) NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cTrial phases differ: Phase 3 versus Phase 4.
- dAssessment timepoints differ: 12 weeks versus 4 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for 13 of these studies.
- gPopulation comparability has not been reviewed for 8 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/vilanterol
show 1 more result
show 6 more results
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 4 more results
+ 10 further endpoints in the CSV export.
Fluticasone propionate/salmeterol (Advair Diskus)
show 2 more results
+ 14 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · Fluticasone propionate/salmeterol (Advair Diskus)'s landscape